Sign in or create an account to add this stock to your watchlist.
About Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.41
Quick Ratio2.41
Price-To-Earnings
Trailing P/E Ratio-4.41
Forward P/E Ratio-3.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.22 million
Price / Sales10.36
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book3.04
Profitability
EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-292.06%
Return on Equity-72.04%
Return on Assets-53.90%
Miscellaneous
Employees280
Outstanding Shares90,960,000
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?
Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Shareholders of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a yield of 17.21%. The ex-dividend date of this dividend is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.22. The biopharmaceutical company had revenue of $1.53 million for the quarter, compared to analyst estimates of $7.50 million. Inovio Pharmaceuticals had a negative return on equity of 72.04% and a negative net margin of 292.06%. During the same quarter in the previous year, the business earned ($0.31) EPS. View Inovio Pharmaceuticals' Earnings History.
What price target have analysts set for INO?
7 analysts have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their forecasts range from $8.00 to $14.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Inovio announced the initiation of a P2 study of DNA-based immunotherapy VGX-3100 for HPV-related (Human Papillomavirus) anal or perianal high-grade squamous intraepithelial lesions (HSIL). This is the third in-house" HPV- related study for VGX-3100; P3 in cervical dysplasia and P2 in high-grade vulvar lesions are both ongoing. In addition, partner MedImmune (AZN – NR) is developing MEDI0457 (VGX-3100 + IL-12 ) for H&N cancer." (5/21/2018)
- 2. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), CryoLife (CRY), K2M Group (KTWO), Cerus (CERS), AtriCure (ATRC), Tactile Systems Technology (TCMD) and MiMedx Group (MDXG).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
- Peter D. Kies, Chief Financial Officer (Age 53)
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
- Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
- George W. Bickerstaff III, Director (Age 62)
- David B. Weiner, Director (Age 61)
- Wendy L. Yarno, Director (Age 63)
- Simon X. Benito, Independent Director (Age 72)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
News headlines about INO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.13 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.15%), Wasatch Advisors Inc. (2.83%), Northern Trust Corp (1.10%), Guggenheim Capital LLC (0.55%), UBS Group AG (0.49%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which institutional investors are selling Inovio Pharmaceuticals stock?
INO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Barclays PLC and Northern Trust Corp. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.
Which institutional investors are buying Inovio Pharmaceuticals stock?
INO stock was purchased by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., New York State Common Retirement Fund and Swiss National Bank. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $4.81.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $453.90 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Inovio Pharmaceuticals (NASDAQ:INO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Inovio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 149.48%. The high price target for INO is $14.00 and the low price target for INO is $8.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.80 | 2.80 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.00 | $20.10 | $19.80 | $20.20 |
| Price Target Upside: | 149.48% upside | 310.20% upside | 373.68% upside | 336.29% upside |
Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History
Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 9/21/2017 | Monthly | $0.0690 | | 9/28/2017 | 9/29/2017 | 10/16/2017 |
| 8/22/2017 | Monthly | $0.0690 | | 8/29/2017 | 8/31/2017 | 9/15/2017 |
| 7/25/2017 | Monthly | $0.0690 | | 7/27/2017 | 7/31/2017 | 8/15/2017 |
| 6/23/2017 | Monthly | $0.0690 | | 6/28/2017 | 6/30/2017 | 7/17/2017 |
(Data available from 1/1/2013 forward)
Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 32.82%
Inovio Pharmaceuticals (NASDAQ INO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | David B Weiner | Director | Sell | 9,000 | $4.91 | $44,190.00 | 758,956 |  |
| 4/12/2018 | Jong Joseph Kim | CEO | Sell | 103,750 | $5.14 | $533,275.00 | 2,395,557 | |
| 4/12/2018 | Simon X Benito | Director | Sell | 3,750 | $5.23 | $19,612.50 | 31,548 | |
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | 740,956 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | 2,164,887 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | 142,291 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | 70,234 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | 142,291 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | 24,048 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | 127,291 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | 32,000 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | 5,965,809 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | 655,864 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | | |
(Data available from 1/1/2013 forward)
Inovio Pharmaceuticals (NASDAQ INO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Inovio launches mid-stage study of VGX-3100 in anal precancer
seekingalpha.com - May 21 at 3:11 PM |
 | Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
finance.yahoo.com - May 21 at 3:11 PM |
 | Inovio Pharmaceuticals (INO) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 21 at 11:34 AM |
| Head-To-Head Analysis: Inovio Pharmaceuticals (INO) and GenMark Diagnostics (GNMK)
www.americanbankingnews.com - May 21 at 1:26 AM |
| Inovio Pharmaceuticals (INO) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 18 at 11:20 PM |
| Inovio Pharmaceuticals (INO) Upgraded at BidaskClub
www.americanbankingnews.com - May 18 at 3:09 PM |
 | Inovio Pharma (INO) Says Presentation at ASCO Show Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
www.streetinsider.com - May 17 at 3:11 PM |
| Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
finance.yahoo.com - May 17 at 3:11 PM |
| Inovio Pharmaceuticals (INO) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 16 at 1:49 PM |
| Investors Purchase Large Volume of Call Options on Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - May 16 at 6:36 AM |
| Inovio's HIV vaccine shows positive effect in early-stage study; shares up 8% premarket
seekingalpha.com - May 16 at 5:01 AM |
 | Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses ...
globenewswire.com - May 15 at 3:01 PM |
 | BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial
www.reuters.com - May 15 at 3:01 PM |
| Inovio Pharma (INO) Says HIV Vaccine Sustained Durable Memory Responses Measured One Year After Start of ...
www.streetinsider.com - May 15 at 3:01 PM |
| Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
finance.yahoo.com - May 15 at 3:01 PM |
| Form 4 INOVIO PHARMACEUTICALS, For: May 11 Filed by: DHILLON AVTAR S
www.streetinsider.com - May 15 at 5:19 AM |
| Inovio Pharmaceuticals (INO) Upgraded at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM |
 | Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
www.nasdaq.com - May 11 at 5:19 AM |
| Inovio Pharmaceuticals (INO) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPS
www.americanbankingnews.com - May 10 at 11:33 PM |
| Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 10 at 7:57 PM |
| Maxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price Target
www.americanbankingnews.com - May 10 at 7:51 PM |
| Inovio Pharmaceuticals Q1 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - May 10 at 3:09 PM |
| BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36
www.reuters.com - May 10 at 3:09 PM |
| Inovio Pharmaceuticals (INO) PT Lowered to $13 at RBC Capital
www.streetinsider.com - May 10 at 3:09 PM |
| Edited Transcript of INO earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 3:09 PM |
| Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
finance.yahoo.com - May 10 at 3:09 PM |
| Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
finance.yahoo.com - May 10 at 3:09 PM |
| Inovio's (INO) CEO Joseph Kim on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM |
| BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36
www.reuters.com - May 10 at 5:01 AM |
| Inovio Pharmaceuticals misses by $0.22, misses on revenue
seekingalpha.com - May 10 at 5:01 AM |
| Inovio: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:01 AM |
| Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 10 at 5:01 AM |
| Inovio Pharmaceuticals Inc (INO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 6 at 1:44 AM |
| ValuEngine Upgrades Inovio Pharmaceuticals (INO) to Sell
www.americanbankingnews.com - May 3 at 10:34 PM |
| Inovio Pharmaceuticals (INO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:51 AM |
| Is Inovio Pharmaceuticals, Inc. (INO) a Buy?
finance.yahoo.com - April 30 at 3:09 PM |
| Inovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - April 30 at 3:09 PM |
| Insider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of Stock
www.americanbankingnews.com - April 19 at 7:52 PM |
| Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock
www.americanbankingnews.com - April 13 at 7:27 PM |
| Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 Shares
www.americanbankingnews.com - April 13 at 7:11 PM |
| Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 3:12 PM |
| Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 12 at 11:17 AM |
| BLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits Texas
www.nasdaq.com - April 12 at 5:15 AM |
| Inovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - April 11 at 11:52 PM |
| Inovio Pharma (INO) Awarded up to $56M from CEPI
www.streetinsider.com - April 11 at 3:13 PM |
| Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
globenewswire.com - April 11 at 3:13 PM |
 | $56 million deal: Inovio secures Coalition funding for vaccine candidates
www.bizjournals.com - April 11 at 3:13 PM |
| Inovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim Group
www.americanbankingnews.com - April 11 at 12:37 PM |
| Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:24 AM |
| Inovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement
Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
